Identification of glucagon-like peptide-1 (glp-1) receptor agonists as a potential antidiabetic agent through molecular docking

Intake of the high level of sugar may cause diabetes which is a metabolic disorder. It is characterized by hyperglycemia, glycosuria, hyperlipidemia, negative nitrogen balance, and ketonemia. Types of diabetes are type 1, is dependent on insulin. The pancreatic islets beta cells are destroyed where most of the cases are autoimmune (Type IA) antibodies that destroy beta cells are detectable in blood, but some are idiopathic also (Type IB). Type 2, is the type of diabetes that is independent of insulin. There is a reduction in the insulin level. GLP-1 is an important incretin that will induce insulin from the pancreatic beta-cell. It will inhibit the release of glucagon. The GLP-1 receptors will get activated where the appetite will get suppressed. In this research, we have designed different novel GLP-1 agonists by changing the amino group of ligand pyrazole carboxamide. The designed ligands were docked on protein 5vex. Among these UDI29 is chosen for further studies like interaction, with a bindinghigh affinity of -8.4 kcal/mol.